Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Schrieber SJ, Hawke RL, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Meyers CM, Doo E, Fried MW.

Drug Metab Dispos. 2011 Dec;39(12):2182-90. doi: 10.1124/dmd.111.040212. Epub 2011 Aug 24.

PMID:
21865319
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.

Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL.

Drug Metab Dispos. 2008 Sep;36(9):1909-16. doi: 10.1124/dmd.107.019604. Epub 2008 Jun 19.

PMID:
18566043
[PubMed - indexed for MEDLINE]
Free Article
3.

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ, Berman J, Liu QY, Doo E, Fried MW; SyNCH Trial Group.

J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.

PMID:
19841158
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC.

Drug Metab Dispos. 2008 Jan;36(1):65-72. Epub 2007 Oct 3.

PMID:
17913795
[PubMed - indexed for MEDLINE]
Free Article
5.

An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.

Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, Markowitz JS.

Drug Metab Dispos. 2013 Sep;41(9):1679-85. doi: 10.1124/dmd.113.052423. Epub 2013 Jul 8.

PMID:
23835761
[PubMed - indexed for MEDLINE]
6.

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Miranda SR, Lee JK, Brouwer KL, Wen Z, Smith PC, Hawke RL.

Drug Metab Dispos. 2008 Nov;36(11):2219-26. doi: 10.1124/dmd.108.021790. Epub 2008 Aug 7.

PMID:
18687803
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Brantley SJ, Oberlies NH, Kroll DJ, Paine MF.

J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7. doi: 10.1124/jpet.109.161927. Epub 2009 Nov 24.

PMID:
19934397
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, Federico A.

Free Radic Biol Med. 2012 May 1;52(9):1658-65. doi: 10.1016/j.freeradbiomed.2012.02.008. Epub 2012 Feb 15.

PMID:
22343419
[PubMed - indexed for MEDLINE]
9.

Bioavailability of a silybin-phosphatidylcholine complex in dogs.

Filburn CR, Kettenacker R, Griffin DW.

J Vet Pharmacol Ther. 2007 Apr;30(2):132-8.

PMID:
17348898
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.

Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E.

Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):333-8.

PMID:
2088770
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.

Schandalik R, Gatti G, Perucca E.

Arzneimittelforschung. 1992 Jul;42(7):964-8.

PMID:
1329780
[PubMed - indexed for MEDLINE]
12.

Identification of hepatoprotective flavonolignans from silymarin.

Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5995-9. doi: 10.1073/pnas.0914009107. Epub 2010 Mar 15.

PMID:
20231449
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY.

Gastroenterology. 2007 May;132(5):1925-36. Epub 2007 Feb 21.

PMID:
17484885
[PubMed - indexed for MEDLINE]
14.

Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.

Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ.

Cancer Res. 2005 May 15;65(10):4448-57.

PMID:
15899838
[PubMed - indexed for MEDLINE]
Free Article
15.

Comparative pharmacokinetics of silipide and silymarin in rats.

Morazzoni P, Montalbetti A, Malandrino S, Pifferi G.

Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):289-97.

PMID:
8149949
[PubMed - indexed for MEDLINE]
16.

A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma.

Brinda BJ, Zhu HJ, Markowitz JS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:1-9. doi: 10.1016/j.jchromb.2012.06.003. Epub 2012 Jun 12.

PMID:
22766231
[PubMed - indexed for MEDLINE]
17.

Comparison of activity level among patients with chronic liver disease.

Price JK, Srivastava R, Bai C, Diao G, Gerber LH, Younossi ZM.

Disabil Rehabil. 2013 Jun;35(11):907-12. doi: 10.3109/09638288.2012.712601. Epub 2012 Aug 29.

PMID:
22931359
[PubMed - indexed for MEDLINE]
18.

[Effects of a new pharmacological complex (silybin + vitamin-E + phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study].

Trappoliere M, Federico A, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria M, Loguercio C; Real Sud Group 2.

Minerva Gastroenterol Dietol. 2005 Jun;51(2):193-9. Italian.

PMID:
15990709
[PubMed - indexed for MEDLINE]
19.

Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Althagafy HS, Graf TN, Sy-Cordero AA, Gufford BT, Paine MF, Wagoner J, Polyak SJ, Croatt MP, Oberlies NH.

Bioorg Med Chem. 2013 Jul 1;21(13):3919-26. doi: 10.1016/j.bmc.2013.04.017. Epub 2013 Apr 16.

PMID:
23673225
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.

Gatti G, Perucca E.

Int J Clin Pharmacol Ther. 1994 Nov;32(11):614-7.

PMID:
7874377
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk